PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2922758-0 1989 Effects of subacute administration of physostigmine on blood acetylcholinesterase activity, motor performance, and soman intoxication. Physostigmine 38-51 acetylcholinesterase Rattus norvegicus 61-81 2760844-2 1989 Release was monitored by measuring endogenous ACh when acetylcholinesterase (AChE) was inhibited with physostigmine (30 microM) or by measuring endogenous choline when AChE activity was left intact. Physostigmine 102-115 acetylcholinesterase Rattus norvegicus 55-75 2760844-2 1989 Release was monitored by measuring endogenous ACh when acetylcholinesterase (AChE) was inhibited with physostigmine (30 microM) or by measuring endogenous choline when AChE activity was left intact. Physostigmine 102-115 acetylcholinesterase Rattus norvegicus 77-81 2810114-1 1989 Acute peripheral administration of physostigmine inhibits cortical acetylcholinesterase (AChE) for about 1 hr in the rat and improves performance on learning and memory paradigms after excitotoxic lesions of the nucleus basalis magnocellularis (NBM) in rats. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 67-87 2810114-1 1989 Acute peripheral administration of physostigmine inhibits cortical acetylcholinesterase (AChE) for about 1 hr in the rat and improves performance on learning and memory paradigms after excitotoxic lesions of the nucleus basalis magnocellularis (NBM) in rats. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 89-93 2810114-3 1989 One week of continuous physostigmine infusion in normal animals inhibited cortical AChE activity in a dose-dependent manner. Physostigmine 23-36 acetylcholinesterase Rattus norvegicus 83-87 2499742-4 1989 The effect of cyproheptadine on extinction of conflict behaviour was decreased by co-administration of physostigmine, an acetylcholinesterase inhibitor, but not affected by the concomitant administration of the muscarine receptor agonist oxotremorine. Physostigmine 103-116 acetylcholinesterase Rattus norvegicus 121-141 2646552-2 1989 Experiment 1 replicated the previously reported deficit in conditional learning produced by ibotenate-induced lesions of the ventral pallidum/substantia innominata, but failed to demonstrate any restoration of learning by a subchronic regimen of the acetylcholinesterase inhibitor physostigmine sufficient to produce significant (30%), but equivalent, degrees of inhibition in the frontal cortex of ventral pallidum/substantia innominata-lesioned or sham-operated rats. Physostigmine 281-294 acetylcholinesterase Rattus norvegicus 250-270 4040999-5 1985 These retention deficits could be reversed by the postacquisition administration of the acetylcholinesterase inhibitor, physostigmine. Physostigmine 120-133 acetylcholinesterase Rattus norvegicus 88-108 3058269-3 1988 When the same animals were treated with the acetylcholinesterase inhibitor physostigmine (0.05 mg/kg), however, performance on the behavioral task was not further promoted, and therefore, under these conditions, the cholinergic cortical transplants appear not to be subject to modulation by anticholinesterase drugs. Physostigmine 75-88 acetylcholinesterase Rattus norvegicus 44-64 2854073-1 1988 The reversible acetylcholinesterase inhibitor, physostigmine, stimulated in a dose-dependent manner the accumulation of [3H]inositol monophosphate ([3H]IP1) in lithium-treated neostriatal slices. Physostigmine 47-60 acetylcholinesterase Rattus norvegicus 15-35 2854073-7 1988 The physostigmine dose-response curve for the stimulation of [3H]IP1 accumulation was similar to its dose-response curve to inhibit acetylcholinesterase activity in the neostriatum. Physostigmine 4-17 acetylcholinesterase Rattus norvegicus 132-152 3039125-3 1986 In the presence of the acetylcholinesterase (AChE) inhibitor, physostigmine, these potentials were followed by a slow e.p.s.p. Physostigmine 62-75 acetylcholinesterase Rattus norvegicus 23-43 3039125-3 1986 In the presence of the acetylcholinesterase (AChE) inhibitor, physostigmine, these potentials were followed by a slow e.p.s.p. Physostigmine 62-75 acetylcholinesterase Rattus norvegicus 45-49 3039125-29 1986 amplitude resulted also from inhibition of AChE by application of physostigmine (1-100 microM). Physostigmine 66-79 acetylcholinesterase Rattus norvegicus 43-47 4033355-3 1985 At 30 min pre-soman, guinea pigs and rats received (im) either pyridostigmine (Py) or physostigmine (Ph) to inhibit whole blood AChE from 10 to 70%; at 1 min post-soman (sc), they received (im) atropine (16 mg/kg)/2-PAMCl (50 mg/kg) and mecamylamine (0.8 mg/kg)/atropine (16 mg/kg), respectively. Physostigmine 86-99 acetylcholinesterase Rattus norvegicus 128-132 6202869-5 1984 Whereas the muscarinic agonists pilocarpine and McN-A-343, the nonclassical antagonist pirenzepine, and the acetylcholinesterase inhibitor physostigmine reduced (+)-[3H]CD binding in both tissues, their inhibitory effects were more potent (4- to 77-fold) in cerebral cortical membranes. Physostigmine 139-152 acetylcholinesterase Rattus norvegicus 108-128 6327444-1 1984 The actions of pyridostigmine (Pyr), a quaternary carbamate compound, and physostigmine ( Phy ), a tertiary carbamate, both known for their reversible inhibition of acetylcholinesterase (AChE), were studied on the electrically excitable membrane and acetylcholine (ACh) receptor of the frog cutaneous pectoris, sartorius, and interosseal muscles, as well as the chronically denervated soleus muscle of the rat and myoballs from neonatal rats. Physostigmine 74-87 acetylcholinesterase Rattus norvegicus 165-185 6327444-1 1984 The actions of pyridostigmine (Pyr), a quaternary carbamate compound, and physostigmine ( Phy ), a tertiary carbamate, both known for their reversible inhibition of acetylcholinesterase (AChE), were studied on the electrically excitable membrane and acetylcholine (ACh) receptor of the frog cutaneous pectoris, sartorius, and interosseal muscles, as well as the chronically denervated soleus muscle of the rat and myoballs from neonatal rats. Physostigmine 74-87 acetylcholinesterase Rattus norvegicus 187-191 6327444-1 1984 The actions of pyridostigmine (Pyr), a quaternary carbamate compound, and physostigmine ( Phy ), a tertiary carbamate, both known for their reversible inhibition of acetylcholinesterase (AChE), were studied on the electrically excitable membrane and acetylcholine (ACh) receptor of the frog cutaneous pectoris, sartorius, and interosseal muscles, as well as the chronically denervated soleus muscle of the rat and myoballs from neonatal rats. Physostigmine 90-93 acetylcholinesterase Rattus norvegicus 165-185 6327444-1 1984 The actions of pyridostigmine (Pyr), a quaternary carbamate compound, and physostigmine ( Phy ), a tertiary carbamate, both known for their reversible inhibition of acetylcholinesterase (AChE), were studied on the electrically excitable membrane and acetylcholine (ACh) receptor of the frog cutaneous pectoris, sartorius, and interosseal muscles, as well as the chronically denervated soleus muscle of the rat and myoballs from neonatal rats. Physostigmine 90-93 acetylcholinesterase Rattus norvegicus 187-191 6194444-6 1983 Addition of physostigmine to the atropine + 2-PAM treatment regimen resulted in appreciable AChE reactivation but reduced RNA levels. Physostigmine 12-25 acetylcholinesterase Rattus norvegicus 92-96 7119894-5 1982 The acetylcholinesterase inhibitor physostigmine was as effective as thiamin in decreasing staring in pyrithiamin-treated rats, but its peripherally acting analogue neostigmine had no effect. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 4-24 7180539-5 1982 Adding eserine (10(-5) M) or soman (10(-6) M) to the superfusion medium increased ACh content to 133 +/- 8 pmol and 101 +/- 8 pmol, respectively, and markedly reduced AChE-activity; ChAT activity was not effected. Physostigmine 7-14 acetylcholinesterase Rattus norvegicus 167-171 6255749-8 1980 In the same observation period the activity of AChE in the tibialis muscle of rats was found to be highest after physostigmine injection before administration of DDVP or phospholine. Physostigmine 113-126 acetylcholinesterase Rattus norvegicus 47-51 7336979-1 1981 The early and late effect of three anticholinesterase agents (physostigmine, paraoxon and soman) on core temperature and brain acetylcholinesterase (AcChE) inhibition are compared. Physostigmine 62-75 acetylcholinesterase Rattus norvegicus 127-147 7229989-4 1981 The acetylcholinesterase inhibitor physostigmine improved the low string test scores in 69.2% of trials with the pyrithiamine-treated rats, whereas neostigmine, which acts peripherally, had no effect. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 4-24 155828-1 1979 In vivo inhibition of blood acetylcholinesterase activity by 9-amino-1, 2, 3, 4-tetrahydroacridine, its 7-methoxy derivative and physostigmine was studied in rats. Physostigmine 129-142 acetylcholinesterase Rattus norvegicus 28-48 7398832-3 1980 If the slices were exposed to an acetylcholinesterase (AChE)-inhibitor (paraoxon 1--20 muM, physostigmine 0.1--0.5 muM), the synaptic potentials were potentiated. Physostigmine 92-105 acetylcholinesterase Rattus norvegicus 33-53 7398832-3 1980 If the slices were exposed to an acetylcholinesterase (AChE)-inhibitor (paraoxon 1--20 muM, physostigmine 0.1--0.5 muM), the synaptic potentials were potentiated. Physostigmine 92-105 acetylcholinesterase Rattus norvegicus 55-59 31185278-4 2019 The current experiment examined if systemic administration of the acetylcholinesterase inhibitor physostigmine (PHY) prior to context learning would rescue prefrontal IEG expression and freezing in the CPFE. Physostigmine 97-110 acetylcholinesterase Rattus norvegicus 66-86 1192181-10 1975 Experiments using physostigmine, an AChE inhibitor, demonstrated that inhibition of AChE can potentiate the effects of ACh in unlesioned preparations, but not in lesioned preparations. Physostigmine 18-31 acetylcholinesterase Rattus norvegicus 36-40 1192181-10 1975 Experiments using physostigmine, an AChE inhibitor, demonstrated that inhibition of AChE can potentiate the effects of ACh in unlesioned preparations, but not in lesioned preparations. Physostigmine 18-31 acetylcholinesterase Rattus norvegicus 84-88 4460070-0 1974 The effects of lithium and physostigmine on rat brain acetylcholinesterase activity. Physostigmine 27-40 acetylcholinesterase Rattus norvegicus 54-74 31517779-6 2019 Nicotine and the acetylcholinesterase inhibitor physostigmine reduced the chronotropism of right atria from either NWR or SHR. Physostigmine 48-61 acetylcholinesterase Rattus norvegicus 17-37 31185278-4 2019 The current experiment examined if systemic administration of the acetylcholinesterase inhibitor physostigmine (PHY) prior to context learning would rescue prefrontal IEG expression and freezing in the CPFE. Physostigmine 112-115 acetylcholinesterase Rattus norvegicus 66-86 30682440-1 2019 BACKGROUND: Carbamates physostigmine and pyridostigmine have been used as a pretreatment against poisoning with nerve agents in order to reversibly inhibit and thus protect from irreversible inhibition a portion of acetylcholinesterase (AChE) in brain and respiratory muscles that is crucial for survival. Physostigmine 23-36 acetylcholinesterase Rattus norvegicus 215-235 31003155-5 2019 Then, PBOCCA rats received ip injections with, either vehicle (control group), the muscarinic receptor agonist oxotremorine (0.1 mg/kg), or the acetylcholinesterase inhibitor physostigmine (0.1 mg/kg). Physostigmine 175-188 acetylcholinesterase Rattus norvegicus 144-164 30682440-1 2019 BACKGROUND: Carbamates physostigmine and pyridostigmine have been used as a pretreatment against poisoning with nerve agents in order to reversibly inhibit and thus protect from irreversible inhibition a portion of acetylcholinesterase (AChE) in brain and respiratory muscles that is crucial for survival. Physostigmine 23-36 acetylcholinesterase Rattus norvegicus 237-241 26828299-4 2016 Adult Sprague Dawley male rats received VTA infusion of the acetylcholinesterase inhibitor, physostigmine (0, 1, 2mug/side), immediately prior to the FST, EPM, or SPT. Physostigmine 92-105 acetylcholinesterase Rattus norvegicus 60-80 30176331-11 2018 Oxime HI-6 50 mg/kg reactivated acetylcholinesterase (AChE) in brain inhibited by physostigmine and in diaphragm inhibited by pyridostigmine. Physostigmine 82-95 acetylcholinesterase Rattus norvegicus 54-58 30176331-12 2018 CONCLUSIONS: Mechanism of physostigmine-induced lethal effect is predominantly central and it involves inhibition of brain AChE, while pyridostigmine produces the same effect exclusively outside the central nervous system, by inhibiting AChE in the respiratory muscles. Physostigmine 26-39 acetylcholinesterase Rattus norvegicus 123-127 30176331-12 2018 CONCLUSIONS: Mechanism of physostigmine-induced lethal effect is predominantly central and it involves inhibition of brain AChE, while pyridostigmine produces the same effect exclusively outside the central nervous system, by inhibiting AChE in the respiratory muscles. Physostigmine 26-39 acetylcholinesterase Rattus norvegicus 237-241 30176331-14 2018 The oxime acts as antidote against physostigmine and pyridostigmine poisoning by reactivating AChE in the brain and diaphragm, respectively. Physostigmine 35-48 acetylcholinesterase Rattus norvegicus 94-98 29122691-2 2018 We previously investigated the role of muscarinic receptors in this regulation by administering physostigmine (PHYSO), an acetylcholinesterase inhibitor, to male and female rats pretreated with scopolamine (SCOP), a nonselective muscarinic antagonist. Physostigmine 96-109 acetylcholinesterase Rattus norvegicus 122-142 23671623-5 2013 Physostigmine, which can overcome the blood-brain barrier or neostigmine acting only peripheral, served as acetylcholinesterase inhibitors. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 107-127 27132443-1 2015 OBJECTIVE: To observe the effect of acetylcholine (ACh) on lipopolysaccharide (LPS) induced inflammatory model of rat alveolar macrophages, and to observe the effect of the acetylcholinesterase inhibitor physostigmine (Phy) on the anti-inflammatory effect of ACh. Physostigmine 204-217 acetylcholinesterase Rattus norvegicus 173-193 24595240-5 2014 The AChE inhibitor physostigmine ameliorated the MK801-induced reduction of BDNF mRNA and protein levels, reduced MK801-triggered MMP-2 activity and prevented decreased TIMP-2 mRNA expression. Physostigmine 19-32 acetylcholinesterase Rattus norvegicus 4-8 24890001-10 2014 Physostigmine administration significantly reduced IL-1beta and AChE levels. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 64-68 23913708-8 2013 Acetylcholinesterase inhibition with physostigmine increased ANP secretion concomitantly with a decrease in atrial dynamics in a concentration-dependent manner. Physostigmine 37-50 acetylcholinesterase Rattus norvegicus 0-20 23343118-3 2013 Physostigmine (AChE inhibitor) or saline were administered subcutaneously continuously via implanted minipumps (1.6 micromoles/kg/day) for 3 weeks, followed by cerebral perfusion mapping during treadmill walking using [(14)C]-iodoantipyrine. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 15-19 23529129-5 2013 Consistent with data from in vitro studies, cholinergic activation by systemic application of the acetylcholinesterase inhibitor, physostigmine, resulted in decreased sag amplitude, increased sag time constant and a decrease of the peak resonance frequency. Physostigmine 130-143 acetylcholinesterase Rattus norvegicus 98-118 23671623-12 2013 Neuronal degeneration and the activity of acetylcholinesterase were elevated after surgery with LPS-treatment and reduced by physostigmine and neostigmine. Physostigmine 125-138 acetylcholinesterase Rattus norvegicus 42-62 21924263-10 2011 However, administration of acetylcholinesterase inhibitors, such as physostigmine and galantamine, resulted in amelioration of the hypobaric hypoxia induced deleterious effects. Physostigmine 68-81 acetylcholinesterase Rattus norvegicus 27-47 23445753-3 2013 The aim of this study was to investigate the level of neurodegeneration, expression of proinflammatory cytokines, glutathione and lipid peroxidation after hyperoxia and treatment with the acetylcholinesterase (AChE) inhibitors, physostigmine and donepezil in the brain of neonatal rats. Physostigmine 228-241 acetylcholinesterase Rattus norvegicus 188-208 23445753-3 2013 The aim of this study was to investigate the level of neurodegeneration, expression of proinflammatory cytokines, glutathione and lipid peroxidation after hyperoxia and treatment with the acetylcholinesterase (AChE) inhibitors, physostigmine and donepezil in the brain of neonatal rats. Physostigmine 228-241 acetylcholinesterase Rattus norvegicus 210-214 22738336-2 2012 The present investigation was designed to test the ability of continuous administration, starting at the time of injury, of physostigmine (PHY), an acetylcholinesterase (AChE) inhibitor that crosses the blood-brain barrier (BBB), to ameliorate the alterations of learning and memory induced by cerebral cortex impact injury in rats under isoflurane anesthesia. Physostigmine 124-137 acetylcholinesterase Rattus norvegicus 148-168 22738336-2 2012 The present investigation was designed to test the ability of continuous administration, starting at the time of injury, of physostigmine (PHY), an acetylcholinesterase (AChE) inhibitor that crosses the blood-brain barrier (BBB), to ameliorate the alterations of learning and memory induced by cerebral cortex impact injury in rats under isoflurane anesthesia. Physostigmine 124-137 acetylcholinesterase Rattus norvegicus 170-174 22738336-2 2012 The present investigation was designed to test the ability of continuous administration, starting at the time of injury, of physostigmine (PHY), an acetylcholinesterase (AChE) inhibitor that crosses the blood-brain barrier (BBB), to ameliorate the alterations of learning and memory induced by cerebral cortex impact injury in rats under isoflurane anesthesia. Physostigmine 139-142 acetylcholinesterase Rattus norvegicus 148-168 20981864-6 2011 Physostigmine was the strongest in vitro AChE-inhibitor (IC50 = 0.012 micro m), followed by 7-methoxytacrine, tacrine, pyridostigmine and methylene blue. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 41-45 20023599-3 2010 We hypothesized that similar responses could be elicited by systemic administration of physostigmine, an acetylcholinesterase inhibitor that penetrates the blood brain barrier. Physostigmine 87-100 acetylcholinesterase Rattus norvegicus 105-125 20600173-4 2010 In this study we have investigated the ability of two AChE inhibitors, donepezil (Aricept) and physostigmine, to induce gamma oscillatory activity in rat hippocampal slices; network activity believed to play a role in higher cognitive function. Physostigmine 95-108 acetylcholinesterase Rattus norvegicus 54-58 20661756-12 2010 Repeated physostigmine injections improved rats" spatial memory and increased cerebral ACh and AChE content (p < 0.05). Physostigmine 9-22 acetylcholinesterase Rattus norvegicus 95-99 21116174-1 2011 Acetylcholinesterase inhibitors (AChE-Is), galantamine, physostigmine and tacrine, enhance central levels of synaptic acetylcholine. Physostigmine 56-69 acetylcholinesterase Rattus norvegicus 0-20 19170187-6 2009 In this model, the acetylcholinesterase inhibitor physostigmine is administered at 0.125 mg/kg i.p. Physostigmine 50-63 acetylcholinesterase Rattus norvegicus 19-39 19283689-0 2009 Differential mRNA expression of acetylcholinesterase in the central nervous system of rats with acute and chronic exposure of sarin & physostigmine. Physostigmine 138-151 acetylcholinesterase Rattus norvegicus 32-52 19283689-1 2009 A time-course study was carried out to measure the acetylcholinesterase (AChE) gene expression in the brain of female rats exposed to different doses of sarin and physostigmine. Physostigmine 163-176 acetylcholinesterase Rattus norvegicus 51-71 19283689-1 2009 A time-course study was carried out to measure the acetylcholinesterase (AChE) gene expression in the brain of female rats exposed to different doses of sarin and physostigmine. Physostigmine 163-176 acetylcholinesterase Rattus norvegicus 73-77 18706897-3 2008 Systemic (Experiment 1) and intrahippocampal (Experiment 2) injections of the acetylcholinesterase inhibitor physostigmine were administered to determine if increasing acetylcholine levels would eliminate the behavioral impairment produced by PTD. Physostigmine 109-122 acetylcholinesterase Rattus norvegicus 78-98 18687163-6 2009 We recently showed that LI was disrupted by scopolamine at low doses, and this was reversed by typical and atypical antipsychotic drugs (APDs) and the acetylcholinesterase inhibitor physostigmine. Physostigmine 182-195 acetylcholinesterase Rattus norvegicus 151-171 19077124-10 2009 The AChE inhibitors tacrine and physostigmine enhanced control LTP. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 4-8 18647636-3 2008 Donepezil significantly potentiated the NGF-induced neurite outgrowth in a concentration-dependent manner whereas the AChE inhibitor physostigmine did not alter NGF-induced neurite outgrowth. Physostigmine 133-146 acetylcholinesterase Rattus norvegicus 118-122 18384867-7 2008 Acetylcholinesterase inhibitors and anticholinergics used as prophylactics can offset each other, but exceptions are observed in a previous study when a very potent anticholinergic (scopolamine) or a high dose of procyclidine still results in cognitive deficits in spite of coadministration with physostigmine. Physostigmine 296-309 acetylcholinesterase Rattus norvegicus 0-20 17596712-3 2007 METHODS: We exposed rat hippocampal cultured neurons to BW284C51, the peripheral anionic site inhibitor of AChE, and to the non-selective AChE active site inhibitor, physostigmine for studying the neuronal remodeling of AChE mRNA expression and trafficking. Physostigmine 166-179 acetylcholinesterase Rattus norvegicus 138-142 17596712-3 2007 METHODS: We exposed rat hippocampal cultured neurons to BW284C51, the peripheral anionic site inhibitor of AChE, and to the non-selective AChE active site inhibitor, physostigmine for studying the neuronal remodeling of AChE mRNA expression and trafficking. Physostigmine 166-179 acetylcholinesterase Rattus norvegicus 138-142 15741579-1 2005 OBJECTIVES: Physostigmine is an acetylcholinesterase inhibitor and can produce fasciculations, seizures, bradycardia, and asystole. Physostigmine 12-25 acetylcholinesterase Rattus norvegicus 32-52 15282260-8 2004 Dentate waves were regularly accompanied by sharp waves in field CA3 and were reduced in size by the acetylcholinesterase inhibitor, physostigmine. Physostigmine 133-146 acetylcholinesterase Rattus norvegicus 101-121 15653001-3 2005 Unilateral microinjection of physostigmine, an acetylcholinesterase inhibitor, into the preBotC increased the frequency of respiratory-related rhythmic activity from XIIn to 116+/-13% (mean+/-S.D.) Physostigmine 29-42 acetylcholinesterase Rattus norvegicus 47-67 15496314-2 2004 Other acetylcholinesterase inhibitors also increased the twitches, showing a hierarchy of potencies of galantamine>physostigmine>tacrine>rivastigmine=donepezil. Physostigmine 118-131 acetylcholinesterase Rattus norvegicus 6-26 15265646-2 2004 In this study the model has been utilised to determine the effect of the acetylcholinesterase inhibiting compounds tacrine and physostigmine on spatial working memory deficits associated with the OB rat. Physostigmine 127-140 acetylcholinesterase Rattus norvegicus 73-93 12927583-8 2003 In the presence of eserine (physostigmine), the specific inhibitor of AChE, the inhibitory effect of Pb was potentiated and this was more pronounced at low-concentrations of Pb. Physostigmine 28-41 acetylcholinesterase Rattus norvegicus 70-74 11509196-11 2001 We also found that infusions of the acetylcholinesterase inhibitor physostigmine (10 microg/microl) into the dorsal hippocampus, like intraseptal muscimol (20 ng/0.4 microl), increased open-arm exploration in the plus-maze test, and decreased burying behavior in the shock-probe test. Physostigmine 67-80 acetylcholinesterase Rattus norvegicus 36-56 12445575-1 2002 Five inhibitors of acetylcholinesterase, huperzine A, donepezil, tacrine, rivastigmine and physostigmine, were compared with regard to their effects on different molecular forms of acetylcholinesterase in cerebral cortex, hippocampus, and striatum from the rat brain. Physostigmine 91-104 acetylcholinesterase Rattus norvegicus 181-201 12445575-7 2002 In hippocampus, huperzine A and physostigmine were the most potent inhibitors of G4 acetylcholinesterase, while donepezil and tacrine were most potent against G1 acetylcholinesterase. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 84-104 12213300-4 2002 We found that microinfusions (10 microg/0.5 microl) of the acetylcholinesterase inhibitor physostigmine in either the dorsal or the ventral hippocampus increased rats" open arm exploration in the plus-maze test, and decreased burying behavior in the shock-probe test. Physostigmine 90-103 acetylcholinesterase Rattus norvegicus 59-79 11701190-13 2001 Pyridostigmine and physostigmine each decreased blood acetylcholinesterase levels by approximately 50%. Physostigmine 19-32 acetylcholinesterase Rattus norvegicus 54-74 11701190-14 2001 Physostigmine also decreased brain cortical acetylcholinesterase levels by approximately 50%, while pyridostigmine had no effect on cortical acetylcholinesterase activity. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 44-64 12431752-2 2002 We previously reported that male rats had significantly greater HPA axis responses to stimulation by physostigmine (PHYSO), an acetylcholinesterase (AChE) inhibitor, compared to females. Physostigmine 101-114 acetylcholinesterase Rattus norvegicus 127-147 12431752-2 2002 We previously reported that male rats had significantly greater HPA axis responses to stimulation by physostigmine (PHYSO), an acetylcholinesterase (AChE) inhibitor, compared to females. Physostigmine 101-114 acetylcholinesterase Rattus norvegicus 149-153 11814330-4 2002 Addition of the carbamate acetylcholinesterase (AChE) inhibitor physostigmine (20 microM) to the perfusion buffer also decreased ACh release. Physostigmine 64-77 acetylcholinesterase Rattus norvegicus 48-52 11740913-10 2001 The in vitro activity of human erythrocyte acetylcholinesterase was significantly inhibited by irinotecan (-21.5% at 100 microM) or physostigmine (-84.8% at 1 microM), whereas SN-38 or camptothecin had no effect. Physostigmine 132-145 acetylcholinesterase Rattus norvegicus 43-63 11766895-1 2001 Statistical analysis of EEG spectra averaged over 10-min intervals showed that in rats performing free behavior, peripheral administration of the acetylcholinesterase inhibitor physostigmine induced long-lasting characteristic changes (lasting tens of minutes) in the electrical activity of the dorsal hippocampus (field CAI) and the somatosensory cortex. Physostigmine 177-190 acetylcholinesterase Rattus norvegicus 146-166 11517282-4 2001 In the current experiments, elevating endogenous levels of acetylcholine in ovariectomized rats by 3 d of continuous administration of physostigmine, an acetylcholinesterase inhibitor, increased NMDA receptor binding in CA1 as measured by quantitative autoradiography. Physostigmine 135-148 acetylcholinesterase Rattus norvegicus 153-173 9680262-8 1998 All of the compounds tested were at least several hundred times less potent than physostigmine as AChE inhibitors. Physostigmine 81-94 acetylcholinesterase Rattus norvegicus 98-102 11330337-8 2001 Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent. Physostigmine 99-112 acetylcholinesterase Rattus norvegicus 51-71 10840182-1 2000 The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning. Physostigmine 43-56 acetylcholinesterase Rattus norvegicus 4-24 10840182-1 2000 The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning. Physostigmine 43-56 acetylcholinesterase Rattus norvegicus 26-30 10840182-1 2000 The acetylcholinesterase (AChE) inhibitors physostigmine (PHY), tacrine (THA), and heptylphysostigmine (HEP) have been evaluated as potential therapeutics for treatment of Alzheimer"s disease (AD) and as prophylactics against organophosphate (OP) poisoning. Physostigmine 58-61 acetylcholinesterase Rattus norvegicus 4-24 10221754-4 1999 This increase is completely blocked by the specific AChE inhibitors propidium, physostigmine, DFP and BW 284C51. Physostigmine 79-92 acetylcholinesterase Rattus norvegicus 52-56 10366013-7 1999 Furthermore, the acetylcholinesterase inhibitor, physostigmine (50 microM), decreased the amplitude of the excitatory synaptic potentials, indicating that ambient acetylcholine can depress this potential. Physostigmine 49-62 acetylcholinesterase Rattus norvegicus 17-37 9767635-5 1998 Some of the newly synthesized derivatives, when tested on isolated and/or AChE-enriched rat brain cortex fraction, displayed a selective inhibitory activity and were more active than physostigmine. Physostigmine 183-196 acetylcholinesterase Rattus norvegicus 74-78 11040261-2 2000 This experiment determined whether hippocampal or entorhinal infusions of the acetylcholinesterase inhibitor physostigmine would reverse such impairing effects on spontaneous alternation performance, a measure of spatial working memory. Physostigmine 109-122 acetylcholinesterase Rattus norvegicus 78-98 9405519-4 1997 The effects of the afferent stimulus were greatly enhanced in CA1 neurons exposed to the catalytic AChE inhibitors neostigmine, physostigmine, or 9-amino-1,2,3, 4-tetrahydro-acridine. Physostigmine 128-141 acetylcholinesterase Rattus norvegicus 99-103 9399975-7 1997 When tested in animals pretreated with both omeprazole and physostigmine (a drug able to prevent the enzymatic breakdown of vagally released ACh through the blockade of acetylcholinesterase), 2-deoxy-D-glucose or electrical vagal stimulation significantly increased pepsinogen secretion without affecting acid secretion. Physostigmine 59-72 acetylcholinesterase Rattus norvegicus 169-189 8090809-1 1994 Previous evidence indicated that physostigmine, an acetylcholinesterase inhibitor, facilitated lordosis behavior when administered intraventricularly to cycling female rats on proestrus prior to the onset of natural sexual receptivity, but not when administered to rats on mid-diestrus or diestrus II. Physostigmine 33-46 acetylcholinesterase Rattus norvegicus 51-71 8819182-5 1995 Inhibition of acetylcholinesterase by physostigmine or neostigmine potentiated contractile responses elicited by 5-HT and alpha-Me-5-HT. Physostigmine 38-51 acetylcholinesterase Rattus norvegicus 14-34 7543947-8 1995 Acute treatments with physostigmine, which inhibit cerebral cortical AChE, had no effect on galanin concentrations. Physostigmine 22-35 acetylcholinesterase Rattus norvegicus 69-73 7646566-1 1995 Inhibition of acetylcholinesterase (AChE) in the whole brain, cerebellum, pons, frontal cortex, basal ganglia and medulla oblongata of rat brain by physostigmine (CAS 57-47-6) in vitro was studied. Physostigmine 148-161 acetylcholinesterase Rattus norvegicus 14-34 7646566-1 1995 Inhibition of acetylcholinesterase (AChE) in the whole brain, cerebellum, pons, frontal cortex, basal ganglia and medulla oblongata of rat brain by physostigmine (CAS 57-47-6) in vitro was studied. Physostigmine 148-161 acetylcholinesterase Rattus norvegicus 36-40 7898122-9 1994 (-)-Huperzine-A and (+/-)-huperzine-A were shown to be more potent than physostigmine as inhibitors of acetylcholinesterase in vitro (IC50 = 6 x 10(-7) M). Physostigmine 72-85 acetylcholinesterase Rattus norvegicus 103-123 7981642-5 1994 From these results, it appears that perfusion of physostigmine at a variety of concentrations, changes not only the basal level of acetylcholine induced by the inhibition of acetylcholinesterase but also the relative acetylcholine output induced by systemic treatment with scopolamine. Physostigmine 49-62 acetylcholinesterase Rattus norvegicus 174-194 9343568-1 1994 Physostigmine, a powerful cholinesterase inhibitor, has recently been labelled with 11C in view of its potential application for in vivo imaging of cerebral acetylcholinesterase (AChE) using positron emission tomography. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 157-177 9343568-1 1994 Physostigmine, a powerful cholinesterase inhibitor, has recently been labelled with 11C in view of its potential application for in vivo imaging of cerebral acetylcholinesterase (AChE) using positron emission tomography. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 179-183 9343568-5 1994 The distributions of 11C label and of AChE activity were found to be essentially super-imposable, both after in vivo injection of and after in vitro incubation with [11C]physostigmine. Physostigmine 170-183 acetylcholinesterase Rattus norvegicus 38-42 9343568-7 1994 The fixation of [11C]physostigmine to cerebral tissue was abolished after incubation of the rat brain sections with BW 284C51, a specific AChE inhibitor, but not after incubation with iso-OMPA, a specific inhibitor of butyrylcholinesterase. Physostigmine 21-34 acetylcholinesterase Rattus norvegicus 138-142 9343568-9 1994 These results indicate that autoradiographic images of the rat brain obtained with [11C]physostigmine reflect AChE distribution, thus supporting the use of this radioligand to trace cerebral AChE activity in humans with positron emission tomography. Physostigmine 88-101 acetylcholinesterase Rattus norvegicus 110-114 8332628-0 1993 Effect of physostigmine and exercise on choline acetyltransferase and acetylcholinesterase activities in fast and slow muscles of rat. Physostigmine 10-23 acetylcholinesterase Rattus norvegicus 70-90 8019748-19 1994 Physostigmine, neostigmine, tacrine and DFP (all at 30 microM) each produced near-total (> 96%) inhibition of AChE activity. Physostigmine 0-13 acetylcholinesterase Rattus norvegicus 113-117 8395146-1 1993 Single channel studies carried out in cultured rat myoballs and cultured hippocampal neurons, and ion flux studies performed on Torpedo electrocyte membrane vesicles, showed that physostigmine (Phy), a well-established acetylcholinesterase inhibitor, interacts directly with nicotinic acetylcholine receptors (nAChR). Physostigmine 179-192 acetylcholinesterase Rattus norvegicus 219-239 8513134-1 1993 The cerebral distribution of [11C]physostigmine, an acetylcholinesterase inhibitor, was studied with autoradiography in rats and positron emission tomography in primates. Physostigmine 34-47 acetylcholinesterase Rattus norvegicus 52-72 8513134-3 1993 In primate brain, the early blood-flow dependent distribution of [11C]physostigmine was followed by a rapid redistribution to acetylcholinesterase-rich regions such as the striatum. Physostigmine 70-83 acetylcholinesterase Rattus norvegicus 126-146 8513134-5 1993 These results suggest that [11C]physostigmine is a promising new ligand for in vivo imaging of acetylcholinesterase activity with PET. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 95-115 1528356-6 1992 Other drugs such as physostigmine, echothiophate, BW284C51, tetrahydroaminoacridine, and metrifonate inhibited both aqueous- and detergent-soluble AChE molecular forms with similar potency. Physostigmine 20-33 acetylcholinesterase Rattus norvegicus 147-151 8441737-8 1993 Pretreatment with physostigmine offered marked protection against inhibition of AChE by soman, as shown by enzyme activity determination in different brain regions and in diaphragm muscle. Physostigmine 18-31 acetylcholinesterase Rattus norvegicus 80-84 1491739-2 1992 In the present study, we determined whether a subeffective dose of the serotonergic type-2 receptor antagonist, ketanserin, would augment the facilitative effects produced by the acetylcholinesterase inhibitor, physostigmine, on memory in aged rats using the same task. Physostigmine 211-224 acetylcholinesterase Rattus norvegicus 179-199 1511335-8 1992 Intrathecal administration of physostigmine, an acetylcholinesterase inhibitor, significantly reduced the threshold intensity of conditioning CRD necessary to inhibit the TF reflex to cut off (mean 36.0 +/- 4.0 mmHg; n = 5). Physostigmine 30-43 acetylcholinesterase Rattus norvegicus 48-68 15374451-3 1991 In the aged rats there was a slight increase in acetylcholinesterase activity after physostigmine but no convincing evidence of enhanced (14)C-2-deoxyglucose uptake. Physostigmine 84-97 acetylcholinesterase Rattus norvegicus 48-68 1794099-5 1991 An intraperitoneal injection of physostigmine (0.0032-0.32 mg/kg), an acetylcholinesterase (AChE) inhibitor, significantly ameliorated the spatial memory deficit induced by MS lesion, but hardly affected that by FF lesion. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 92-96 1794099-5 1991 An intraperitoneal injection of physostigmine (0.0032-0.32 mg/kg), an acetylcholinesterase (AChE) inhibitor, significantly ameliorated the spatial memory deficit induced by MS lesion, but hardly affected that by FF lesion. Physostigmine 32-45 acetylcholinesterase Rattus norvegicus 70-90 1946575-1 1991 This study sought to determine whether the choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) enzymes in the brain were affected in a regionally selective manner by chemical and physical stressors: 1) subacute administration of physostigmine (Phy); 2) exercise; and 3) the combination of these two stressors. Physostigmine 242-255 acetylcholinesterase Rattus norvegicus 80-100 2875917-5 1986 Addition of the acetylcholinesterase inhibitor, physostigmine, caused a leftward shift in the GABA dose-response curve and increased by 10-fold the sensitivity of the antral preparation to GABA stimulation. Physostigmine 48-61 acetylcholinesterase Rattus norvegicus 16-36 2217513-2 1990 The present study examined the facilitative effects of the acetylcholinesterase inhibitor, physostigmine (eserine), on sexual behavior in intact, cycling female rats. Physostigmine 91-104 acetylcholinesterase Rattus norvegicus 59-79 25865152-4 2015 Here, male Sprague-Dawley rats received systemic or VTA-specific administration of the acetylcholinesterase inhibitor, physostigmine (systemic; 0.06 or 0.125mg/kg, intra-cranial; 1 or 2mug/side), the muscarinic acetylcholine receptor (AChR) antagonist scopolamine (2.4 or 24mug/side), or the nicotinic AChR antagonist mecamylamine (3 or 30mug/side), prior to the FST test session. Physostigmine 119-132 acetylcholinesterase Rattus norvegicus 87-107 33766648-8 2021 Studies also showed that these pesticides and eserine decreased three to five times the acetylcholinesterase activity in the serum compared to controls whereas terminal end buds increased in number, being inhibited by atropine. Physostigmine 46-53 acetylcholinesterase Rattus norvegicus 88-108